Skip to content
Preprint · OA via OpenAlex

Biological age measured by DNA methylation clocks and neurodegenerative diseases: A systematic review and meta-analysis

Zaylea Kua, Jian Hua Tay, Audrey Low, Weilan Wang, B.T. Thomas Yeo, Yanhong Dong, Nagaendran Kandiah, Geert Jan Biessels, Andrea Britta Maier

medRxiv · 2026

Abstract

Hallmarks of biological ageing are closely interconnected with neurodegenerative diseases. Deoxyribonucleic acid methylation (DNAm) clocks quantify biological age and may serve as peripheral biomarkers of neurodegenerative diseases. This systematic review and meta-analysis aim to examine associations between DNAm-based biological age metrics and neurodegenerative diseases. Six databases were systematically searched from 1st January 2011 to 15th April 2026 for studies reporting associations between DNAm-based ages and neurodegenerative diseases including all-cause dementia, Parkinson's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis. Correlated-and-hierarchical-effects meta-analyses were fitted using restricted maximum likelihood with Knapp-Hartung adjustment. Of 42,023 records screened, 37 observational studies (n=46365; 60.5% female; median of mean age 69.4 years [IQR 62.5-73.3)) and seven Mendelian randomization studies met inclusion criteria. In longitudinal meta-analyses, higher GrimAge epigenetic age acceleration (EAA) was significantly associated with higher dementia risk (HR per SD 1.11 [95% CI 1.02-1.20]; I^2 = 0.0%; p = 0.018), whereas Horvath1 EAA, Hannum EAA, PhenoAge EAA, and DunedinPACE were not significantly associated with dementia risk. Evidence for other neurodegenerative diseases were heterogeneous across clock generations and study designs. Mendelian randomization provided limited evidence for causality. Higher GrimAge EAA was the only DNAm age measure consistently predictive of higher all-cause dementia risk. Overall, however, DNAm age clocks show limited and inconsistent associations with neurodegenerative diseases, providing insufficient support for their use as disease biomarkers. These findings highlight the need to develop and independently validate disease-specific DNAm clocks and undertake pathway analyses to identify methylation changes associated with neurodegeneration and the biological processes they reflect.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.64898/2026.10.21.26365867
Canonical
link ↗
Fetched
2026-10-23 MST

Cite this

APA
Kua, Z., Tay, J.H., Low, A., Wang, W., Yeo, B.T., Dong, Y., Kandiah, N., Biessels, G.J., &amp; Maier, A.B. (2026). Biological age measured by DNA methylation clocks and neurodegenerative diseases: A systematic review and meta-analysis. <em>medRxiv</em>. https://doi.org/10.64898/2026.10.21.26365867
Vancouver
Kua Z, Tay JH, Low A, Wang W, Yeo BT, Dong Y, et al. Biological age measured by DNA methylation clocks and neurodegenerative diseases: A systematic review and meta-analysis. medRxiv. 2026. doi:10.64898/2026.10.21.26365867.
BibTeX
@unpublished{zaylea2026Biolog, title = {Biological age measured by DNA methylation clocks and neurodegenerative diseases: A systematic review and meta-analysis}, author = {Zaylea Kua and Jian Hua Tay and Audrey Low and Weilan Wang and B.T. Thomas Yeo and Yanhong Dong and Nagaendran Kandiah and Geert Jan Biessels and Andrea Britta Maier}, journal = {medRxiv}, year = {2026}, doi = {10.64898/2026.10.21.26365867}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings